Close this search box.

Viewpoint Molecular Targeting™ Announces Strategic Partnership with Eichrom Technologies to Accelerate Isotope Production Process Development

Automation of manufacturing is critical to scaling Viewpoint’s isotope production technologies in a way that is safe for personnel and cost effective

Coralville, IA, April 6, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has established a strategic partnership with Eichrom Technologies, LLC (“Eichrom”) to accelerate the automation and scale up of Viewpoint’s isotope production process.

Eichrom is a world leader in radiometal separations and chromatography technologies that play a central role in radiopharmaceutical development and production. The company operates a subsidiary called Nuclear Power Outfitters (“NPO”) that specializes in custom radiation shielding for the nuclear industry. Eichrom and NPO represent an ideal supplier of Pb-212 generator pre-assemblies for manufacturing as well as a world-class organization with vast knowledge of radiometal purifications and radiation safety components for Viewpoint applications.

“By working with the team at Eichrom, we gain decades of experience in optimizing the key aspects of radiometal chromatography for our isotope production technologies. In addition, NPO is a nimble-custom radiation shielding partner with deep experience and knowledge that can be implemented as our production process is scaled up. We have had a long-standing supplier relationship with both of these great teams, and we are excited to further strengthen our relationship as a means to accelerate our manufacturing roll out,” commented Michael Schultz, PhD, Chief Science Officer of Viewpoint.

Click here for the full press release.